These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 17414683

  • 21. Selecting appropriate treatments for maintenance therapy for bipolar disorder.
    Thase ME.
    J Clin Psychiatry; 2008; 69 Suppl 5():28-35. PubMed ID: 19265638
    [Abstract] [Full Text] [Related]

  • 22. Maintenance treatment of bipolar disorders.
    Rybakowski J.
    Neuro Endocrinol Lett; 2005 Aug; 26 Suppl 1():49-65. PubMed ID: 16361988
    [Abstract] [Full Text] [Related]

  • 23. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J, Postma MJ, Bruggeman R, De Jong-Van Den Berg LT, Van Den Berg PB, Stolk RP, Burger H.
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [Abstract] [Full Text] [Related]

  • 24. Quality of life in the long-term treatment and the role of second-generation antipsychotics.
    Mohr P.
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():117-33. PubMed ID: 17262004
    [Abstract] [Full Text] [Related]

  • 25. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
    Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP, Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness.
    J Clin Psychiatry; 2009 Feb; 70 Suppl 4():1-46; quiz 47-8. PubMed ID: 19686636
    [Abstract] [Full Text] [Related]

  • 26. Atypical antipsychotics as "mood stabilizers": a retrospective chart review.
    Savas HA, Yumru M, Kaya MC, Selek S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun 30; 31(5):1064-7. PubMed ID: 17449159
    [Abstract] [Full Text] [Related]

  • 27. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications.
    Brugue E, Vieta E.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan 30; 31(1):275-82. PubMed ID: 16876306
    [Abstract] [Full Text] [Related]

  • 28. Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients.
    Rosa AR, Marco M, Fachel JM, Kapczinski F, Stein AT, Barros HM.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan 30; 31(1):217-24. PubMed ID: 16982121
    [Abstract] [Full Text] [Related]

  • 29. Long-term pharmacological treatment of bipolar disorders.
    Rybakowski J.
    Neuro Endocrinol Lett; 2007 Feb 30; 28 Suppl 1():71-93. PubMed ID: 17262006
    [Abstract] [Full Text] [Related]

  • 30. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS, Stewart DW.
    J Psychopharmacol; 2006 Nov 30; 20(6 Suppl):20-37. PubMed ID: 17046985
    [Abstract] [Full Text] [Related]

  • 31. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J.
    Eur Neuropsychopharmacol; 2009 Jul 30; 19(7):520-32. PubMed ID: 19411165
    [Abstract] [Full Text] [Related]

  • 32. Atypical antipsychotics in the treatment of mood disorders.
    Jarema M.
    Curr Opin Psychiatry; 2007 Jan 30; 20(1):23-9. PubMed ID: 17143078
    [Abstract] [Full Text] [Related]

  • 33. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H, Stompe T.
    Neuropsychiatr; 2010 Jan 30; 24(1):14-26. PubMed ID: 20146916
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Risks versus benefits of different types of long-acting injectable antipsychotics.
    McEvoy JP.
    J Clin Psychiatry; 2006 Jan 30; 67 Suppl 5():15-8. PubMed ID: 16822092
    [Abstract] [Full Text] [Related]

  • 36. Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.
    Keramatian K, Chakrabarty T, Yatham LN.
    CNS Drugs; 2019 May 30; 33(5):431-456. PubMed ID: 30963507
    [Abstract] [Full Text] [Related]

  • 37. Improving treatment adherence in bipolar disorder through psychoeducation.
    Vieta E.
    J Clin Psychiatry; 2005 May 30; 66 Suppl 1():24-9. PubMed ID: 15693749
    [Abstract] [Full Text] [Related]

  • 38. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF, Cheng CP, Huang CF, Yen JY, Ko CH, Chen CS.
    Bipolar Disord; 2008 Jul 30; 10(5):617-24. PubMed ID: 18657246
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P, Bret MC, Queuille E.
    Encephale; 2009 Apr 30; 35(2):129-38. PubMed ID: 19393381
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.